Welcome to our dedicated page for SOPHiA GENETICS SA Ordinary Shares news (Ticker: SOPH), a resource for investors and traders seeking the latest updates and insights on SOPHiA GENETICS SA Ordinary Shares stock.
SOPHiA GENETICS SA (Nasdaq: SOPH) is a leader in the field of data-driven medicine, leveraging cutting-edge technology to advance healthcare. Based in Switzerland, the company is renowned for its high medical standards and precision. SOPHiA GENETICS has built the SOPHiA DDM™ Platform, a cloud-based SaaS platform designed to analyze complex genomic and multimodal data, delivering valuable insights for clinical and life sciences research.
Through its innovative platform, SOPHiA GENETICS supports healthcare professionals in over 100 hospitals globally, enabling them to perform faster and more accurate diagnoses using next-generation sequencing (NGS) analytics. The platform also facilitates knowledge sharing within the largest clinical genomics community.
Recently, SOPHiA GENETICS has made significant strides with several notable partnerships:
- Unilabs, a prominent European diagnostic provider, adopted the SOPHiA DDM™ Platform to enhance their HRD-status testing capabilities in solid tumors.
- Syndicate Bio in Nigeria integrated MSK-ACCESS® powered by SOPHiA DDM™, marking the first comprehensive genomic profiling and liquid biopsy availability across Africa.
- Klinikum Klagenfurt in Austria and Instituto Mário Penna in Brazil have also implemented the platform to advance their cancer diagnostics and treatment planning, particularly in blood-related cancers and disorders.
Financially, SOPHiA GENETICS is recognized for its robust operational execution and business momentum, continually reaffirming its guidance. The company is actively collaborating with tech giants like Microsoft and NVIDIA to develop a streamlined whole genome sequencing (WGS) analytical solution, promising rapid and precise insights aiding clinical decision-making.
SOPHiA GENETICS also launched SOPHiA UNITY, a global consortium to accelerate cancer research by harnessing diverse, high-quality data from leading institutions worldwide. The platform’s advanced AI-based technology and proprietary algorithms will support decision-making and expedite oncology research.
For more information, visit SOPHiAGENETICS.com or connect on LinkedIn, X, Facebook, and Instagram.
SOPHiA GENETICS (NASDAQ: SOPH), a cloud-native software company, has partnered with Memorial Sloan Kettering Cancer Center (MSK) to enhance cancer testing and analytics. This collaboration focuses on the MSK-ACCESS® sequencing tests, the first comprehensive ctDNA liquid biopsy test leveraging the SOPHiA DDM™ Platform. Both parties aim to develop a clinico-genomic analytics platform, utilizing advanced machine learning to improve global cancer care. The partnership was announced ahead of the 41st annual JP Morgan Healthcare Conference on January 10, 2022.
SOPHiA GENETICS (NASDAQ: SOPH) announced that CEO Dr. Jurgi Camblong will present at the J.P. Morgan 2023 Healthcare Conference on January 10, 2023, at 8:15 a.m. PST in
SOPHiA GENETICS (Nasdaq: SOPH) reported Q3 2022 revenue of $11.6 million, a 12% increase year-over-year, with constant currency growth of 40% excluding COVID-19 revenues. The company improved its operating loss to $23.6 million, reflecting progress in its sustainable growth strategy. Gross profit rose to $7.3 million, maintaining a gross margin of 63%. Total operational expenses increased to $30.9 million. For full-year 2022, SOPHiA expects revenue to be at the low-end of the guidance range of $47.0 million to $49.5 million due to foreign exchange factors.
SOPHiA GENETICS (Nasdaq: SOPH) announced its participation in two upcoming investor conferences. The company will hold a fireside chat at the Evercore ISI HealthCONx Virtual Conference on November 29 at 2:15 PM EST and at the Credit Suisse 26th Annual Technology Conference on November 30 at 1:40 PM MST. Live and archived webcasts can be accessed through the Investor Relations section of their website. SOPHiA GENETICS focuses on data-driven medicine through its SOPHiA DDM™ Platform, serving numerous healthcare institutions globally.
SOPHiA GENETICS (Nasdaq: SOPH) has announced a multi-year strategic partnership with Microsoft on Nov. 1, 2022, to enhance healthcare workflows globally through its SOPHiA DDM™ health data analysis platform, powered by Microsoft Azure. This collaboration aims to break down data silos and facilitate multimodal data curation, improving clinical outcomes and patient care. The partnership will enable healthcare providers to deliver precision medicine more effectively, leveraging AI and machine learning technologies to generate actionable insights for improved health outcomes.
SOPHiA GENETICS (Nasdaq: SOPH) will release its Q3 fiscal 2022 financial results on November 8, 2022, before U.S. markets open. The company plans to host a conference call at 8:30 a.m. EST to discuss these results and its business outlook. Investors can access the call via the SOPHiA GENETICS Investor Relations website, where a replay will be available afterward. The firm focuses on data-driven medicine, offering the SOPHiA DDM™ Platform used by various healthcare institutions globally.
SOPHiA GENETICS, a cloud-native software company focused on data-driven medicine, hosted its inaugural Investor Day in New York on September 20, 2022. Major highlights included a memorandum of understanding with Memorial Sloan Kettering Cancer Center to enhance cancer genomics and a partnership with Boundless Bio for developing precision oncology therapies targeting extrachromosomal DNA in oncogene amplified cancers. The event showcased SOPHiA's CarePath solution, which leverages real-world data and aims to transform patient care and research.
SOPHiA GENETICS (Nasdaq: SOPH) hosted its inaugural Investor Day in New York City on September 20, 2022. The event featured key presentations from executive leaders discussing the company's growth strategies and unique differentiators in the healthcare technology space. Attendees included the board chairman, CEO, and various chief officers, aiming to enhance investor understanding of SOPHiA's data-driven medicine approach. The event was open to registered participants and provided a webcast option for broader access.
SOPHiA GENETICS (Nasdaq: SOPH) announced that CEO Dr. Jurgi Camblong and CFO Ross Muken will participate in a fireside chat at the 20th Annual Morgan Stanley Global Healthcare Conference. This event will take place on September 12, 2022, at 8:45 a.m. EDT. SOPHiA GENETICS is a cloud-native software company focused on data-driven medicine, utilizing its SOPHiA DDM™ Platform for analyzing complex multimodal data sets. Its solutions are widely used by hospitals, laboratories, and biopharma institutions globally.
SOPHiA GENETICS (Nasdaq: SOPH) reported Q2 2022 revenue of $11.7 million, a 15% increase from Q2 2021. Excluding COVID-19 revenues, constant currency growth was 36%. Gross margin improved to 65%, with a record adjusted gross margin of 67%. However, operating loss widened to $24.1 million, up from $15.9 million year-over-year. The company maintained its revenue growth guidance for FY 2022 at 30% to 35%, though overall revenue is now expected between $47 million and $49.5 million due to currency fluctuations.
FAQ
What is the current stock price of SOPHiA GENETICS SA Ordinary Shares (SOPH)?
What is the market cap of SOPHiA GENETICS SA Ordinary Shares (SOPH)?
What does SOPHiA GENETICS do?
What is the SOPHiA DDM™ Platform?
Where is SOPHiA GENETICS based?
Who are some of SOPHiA GENETICS' partners?
What is SOPHiA UNITY?
How does SOPHiA GENETICS support precision medicine?
What recent advancements have SOPHiA GENETICS made?
What is the company's mission?
How does SOPHiA GENETICS ensure data privacy and quality?
How can I learn more about SOPHiA GENETICS?
